Evaluation of Exposure Reduction Using Region-of-Interest Fluoroscopy (X-ray Fovea Imaging) in Cardiac Interventions

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Sunnybrook Health Sciences Centre.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
General Electric
Information provided by:
Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier:
NCT00817115
First received: November 14, 2008
Last updated: August 6, 2009
Last verified: January 2009
  Purpose

The aim of the proposed study is to compare the exposure dose and diagnostic performance of region-of-interest fluoroscopy compared to standard fluoroscopy in patients and interventionists during cardiac interventional procedures. It is hypothesized that systematic application of x-ray attenuation will significantly reduce the radiation exposure of the interventional procedure while maintaining image quality, thereby decreasing risk to the patient.


Condition Intervention Phase
Cardiovascular Diseases
Device: Region-of-Interest Imaging (X-ray Fovea Imaging)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Trial to Determine Non-inferiority of Exposure Dose Reduction and Diagnostic Performance of Region-of-Interest Fluoroscopy (X-ray Fovea Imaging) Compared to Standard Fluoroscopy in Patients Undergoing Cardiac Interventional Procedures

Resource links provided by NLM:


Further study details as provided by Sunnybrook Health Sciences Centre:

Primary Outcome Measures:
  • X-ray exposure area product, primary and scatter radiation to patient and interventionist and procedure and irradiation time for interventions performed without and with region-of-interest imaging (control and experimental arms, respectively). [ Time Frame: The outcome measure will be recorded per patient procedure. A comparison between control and experimental arms will be conducted after the pilot study (at ~1 to 2 months) and at end the full study (at ~4 to 6 months). ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Quality and diagnostic benefit of images obtained without and with the region-of-interest imaging. [ Time Frame: Retrospective expert comparison of images from patient procedures (between control and experimental arms) will occur within 1 to 3 months after the completion of the pilot study and the full study. ] [ Designated as safety issue: No ]

Estimated Enrollment: 75
Study Start Date: February 2009
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: 1
Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
Experimental: 2
Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
Device: Region-of-Interest Imaging (X-ray Fovea Imaging)
Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.

Detailed Description:

X-ray catheterization is used to guide minimally invasive procedures including percutaneous coronary interventions (PCIs), involving diffuse and multiple vessel disease and total chronic occlusion as well as electrophysiology (EP) procedures. While the medical benefit to patients outweighs the procedural risk, long fluoroscopy times associated with complex interventions have resulted in acute radiation injuries to patients. Radiation induced cancers have also become a concern in younger patient populations. With the increased number, diversity and complexity of the interventions performed, there has been a growing interest in reducing the long-term exposure risk to medical personnel (interventionists).

Conventional methods to reduce in radiation exposure, however, impact and often degrade diagnostic image quality. Catheterization procedures focus on a small portion of the anatomy forming the central region of the image with the periphery providing contextual information. Thus, decreasing the image quality in periphery can provide an overall exposure reduction to patients and interventionists without impacting on diagnosis. This can be achieved by introducing a pre-patient region-of-interest (ROI) attenuator that collimates the primary x-ray beam, reducing exposure to peripheral regions and decreasing integral radiation to the patient and scatter radiation to the interventionist.

The goal of this study is to investigate the exposure dose reduction provided by ROI imaging to patients and interventionists undergoing catheterization and to examine the feasibility of using the ROI attenuator in routine clinical practice for future integration into commercial x-ray imaging systems. The aim is to obtain exposure dose data and cardiac angiography images from subjects undergoing routine interventional procedures performed with and without ROI attenuation (experimental and control groups, respectively). For the experimental group, the interventionists performing the procedure will determine the appropriate application of the ROI attenuator and the duration of its use on specific patient lesions. An internal pilot study will be initially conducted on approximately 30 patients (15 per group) to obtain estimates on patient and operator dose reduction and variability. The on-going clinical trial will then be performed on an additional 40 patients (where the final protocol procedures and recruitment will be refined based on results from the pilot study).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject is greater than 18 years of age.
  • The subject is currently planned for conventional cardiac interventional procedures (i.e. catheterization, percutaneous coronary intervention (PCI), electrophysiology (EP) ablations and procedures) as specified by his/her physician.
  • The subject is able and willing to comply with study procedures, and signed and dated informed consent is obtained.

Exclusion Criteria:

  • The subject is pregnant or trying to become pregnant.
  • The subject requires urgent/emergent cardiac catheterization, PCI, and/or EP procedures as per treating physician.
  • The subject has been previously included in the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00817115

Locations
Canada, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
General Electric
Investigators
Principal Investigator: Alexander J Dick, MD Sunnybrook Health Sciences Centre
Study Director: Normand Robert, PhD Sunnybrook Health Sciences Centre
Study Chair: John A Rowlands, PhD Sunnybrook Health Sciences Centre
  More Information

No publications provided

Responsible Party: Dr. Alexander Dick, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT00817115     History of Changes
Other Study ID Numbers: 005-2008
Study First Received: November 14, 2008
Last Updated: August 6, 2009
Health Authority: Canada: Ethics Review Committee

Keywords provided by Sunnybrook Health Sciences Centre:
Region-of-Interest Imaging
X-ray Fovea Imaging
Cardiovascular Diseases
Radiation Dosage
Radiographic Image Enhancement
Radiography, Interventional

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on April 17, 2014